Short description
Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases
Description
Genascence is a clinical-stage biotechnology company that is using gene therapy to revolutionize the treatment of common musculoskeletal diseases. The company intends to tackle one of the most serious problems in medicine: osteoarthritis, which is the leading cause of disability, chronic pain, and a significant risk factor for opioid addiction (OA).
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Palo Alto, California, United States, North America
Founded on
January 1, 2017
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Blurry Noaccess, Noaccess, Noway Youcantaccess, Noaccessforu, Noway Youcantaccess
Sign in for full access
Founders
Thomas W. Chalberg, PhD